GSK Thinks It Can Build a Better Flu Shot With mRNA

A Crowded Race With One Clear Leader

GSK isn't the only pharma giant chasing the mRNA flu dream. But the competitive landscape has sorted itself into a surprisingly clear pecking order.

Moderna is already across the finish line. Its mRNA flu vaccine, mFLUSIVA, received FDA approval in August 2026 for adults 50 and older, making it the first commercially available mRNA flu shot. The company is rolling it out for the 2026–2027 season and pursuing regulatory reviews in Europe, Canada, and Australia.

Pfizer is still developing mRNA flu candidates but hasn't reached Moderna's stage. Sanofi, meanwhile, has essentially hit the pause button on its mRNA seasonal flu program altogether, though it's still poking around with a pandemic flu (H5) mRNA study in early-stage trials.

That leaves GSK as the most credible late-stage challenger to Moderna's head start. The FDA apparently agrees that GSK's program has promise: it granted the vaccine Fast Track designation in July 2026, a regulatory nod that can speed up the review process.

The Stakes Are Enormous (and Mostly Untapped)

The global seasonal flu vaccine market sits at roughly $9.5 to $10 billion in 2026, and it's growing at a healthy clip. But the mRNA slice of that pie is still tiny. One market analysis pegged the global mRNA influenza vaccine market at just $30 million in 2026, a rounding error compared to the broader market.

The long-term potential tells a different story. That same analysis projects mRNA flu vaccines could reach over $840 million in North America alone by 2034. The technology is at an inflection point: small revenue today, but positioned to grab meaningful market share as more products get approved and doctors grow comfortable prescribing them.

For GSK, success here would do more than just add a product to the portfolio. It would validate the company's entire mRNA platform, which traces back to a 2020 partnership with CureVac. GSK originally teamed up with the German biotech to co-develop up to five mRNA vaccines and therapies. It has since restructured the deal to take full control of development, manufacturing, and worldwide commercial rights for the most advanced candidates, including this flu vaccine.

The Catch: Phase 2 Hype Doesn't Always Survive Phase 3

Before anyone starts popping champagne, it's worth remembering an uncomfortable truth about drug development. Strong immune responses in a mid-stage trial don't automatically translate into real-world protection against the flu. The antibodies looked great in 971 patients. The question is whether that translates to fewer people actually getting sick across tens of thousands.

Phase 3 is where vaccines go to prove they work in the real world, not just on a lab readout. Plenty of promising candidates have stumbled at this stage. The trial registered for adults 18 to 64 is expected to run through mid-2027, with a broader study extending into 2028. Investors and analysts will be watching those efficacy numbers closely.

What This Means for You

If you're an investor, GSK's mRNA flu program just became one of the most interesting pipeline stories in vaccines. The Phase 2 data is legitimately strong, the competitive positioning is favorable (only Moderna is ahead), and the addressable market is massive. But it's still a Phase 3 bet, and those come with real risk.

If you're a regular person who gets a flu shot every year, the bigger picture is this: the technology behind your COVID vaccine is starting to reshape how we fight the flu. The egg-based status quo has dominated for over half a century. Within a few years, you might have meaningfully better options.

The mRNA revolution didn't end with COVID. It's just getting started.

The $116.7M Bet on the Immune System's Secret Police Force

TRex Bio just went public with $117 million and Eli Lilly as its biggest shareholder, all to boost the immune system's own peacekeeping cells. The Treg therapy space is heating up fast, and the race to reinvent autoimmune treatment is officially on.